Leti Startup to Provide Improved Cancer Surgery
News Jun 30, 2009
Leti has announced that it has launched a new company, Fluoptics that is expected to improve surgery of some types of cancers.
Combining technologies developed by Leti and Université Joseph Fourier in Grenoble, Fluoptics developed an innovative approach of fluorescence imaging for cancer targeting. This new real-time, imaging technique improves detection of tumors and helps surgeons to delineate it for exerese.
Fluoptics, the 30th startup launched by Leti, expects to commercialize its FluoBeam instrument in 2010 for pre-clinical research and begin regulatory the toxicity phases of its first fluorescent marker.
“Fluoptics not only exemplifies Leti’s mission of creating innovation and transferring it to industry, but it also is our first startup in the growing field of bio-medicine,” said Laurent Malier, CEO of Leti. “The company has great potential to improve the detection and treatment of cancer, and to have a real impact on the lives of cancer patients.”
“It is very difficult to distinguish between cancerous and healthy tissue, and our technology is the only intra-operative technique available to help surgeons precisely locate and delineate tumors,” said Odile Allard, CEO of Fluoptics. “Our incubation in Leti enabled the finalization of the laboratory prototype and its preclinical validation by surgeons specialized in cancer.”
Fluoptics, one of the four startups launched by Leti in the past year, will be based in MINATEC.
A new experimental system has been designed that can rapidly assess the pathogenic effects of a drug on a baby's developing brain. The system uses embryonic stem cells reprogrammed into neurons, and offers a powerful tool for probing genetic and molecular underpinnings of drug-induced neurodevelopmental disorders.READ MORE
An investigational drug for the treatment of sickle cell disease shows early promise in Phase 2a clinical trial. The orally administered drug, given to adult patients with sickle cell disease, is demonstrating tolerability and the ability to impact both red and white blood cell biomarkers of the disease.READ MORE